Omega-3 phospholipid - Grace Therapeutics
Alternative Names: CaPre; Long-chain-omega-3-phospholipid; NKPL-66Latest Information Update: 29 Oct 2024
Price :
$50 *
At a glance
- Originator Acasti Pharma
- Developer Grace Therapeutics
- Class Antihyperlipidaemics; Omega 3 fatty acids; Phospholipids
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus; Hypertriglyceridaemia
Most Recent Events
- 25 Oct 2024 Acasti Pharma is now called Grace Therapeutics
- 31 Aug 2020 Acasti Pharma decides to not submit NDA for Hypertriglyceridaemia (PO) to the US FDA (due to failure in meeting primary endpoint in TRILOGY 2 trial)
- 31 Aug 2020 Top-line efficacy and adverse events data from the phase III TRILOGY 2 study in Hypertriglyceridaemia released by Acasti Pharma